Cesca Therapeutics Inc  

(Public, NASDAQ:KOOL)   Watch this stock  
Find more results for Marrow
0.680
+0.055 (8.80%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.63 - 0.72
52 week 0.58 - 1.41
Open 0.67
Vol / Avg. 55,794.00/28,441.00
Mkt cap 27.51M
P/E     -
Div/yield     -
EPS -0.39
Shares 40.45M
Beta 0.67
Inst. own 14%
Sep 28, 2015
Q4 2015 Cesca Therapeutics Inc Earnings Release (Estimated) Add to calendar
Sep 10, 2015
Cesca Therapeutics Inc at Rodman & Renshaw Global Investment Conference - 3:25PM EDT - Add to calendar
Jun 23, 2015
Q3 2015 Cesca Therapeutics Inc Earnings Call
Jun 23, 2015
Q3 2015 Cesca Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -119.03% -53.99%
Operating margin -119.64% -56.55%
EBITD margin - -50.53%
Return on average assets -35.27% -21.20%
Return on average equity -49.10% -27.83%
Employees 95 -
CDP Score - -

Address

2711 Citrus Road
RANCHO CORDOVA, CA 95742
United States - Map
+1-916-8585100 (Phone)
+1-916-8585199 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cesca Therapeutics Inc., formerly ThermoGenesis Corp., is focused on the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is engaged in developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. It focuses in three target markets to serve patients, physicians and partners: Cellular Therapeutics, Medical/Diagnostic Device Development and Commercialization and Cell Manufacturing and Banking. It is a regenerative medicine company with the ability to research, design and develop devices and disposables necessary to facilitate clinical protocols and applications directed at cell therapies at the point of care.

Officers and directors

Craig W. Moore Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Kenneth L. Harris President, Director
Age: 51
Bio & Compensation  - Reuters
Robin C. Stracey Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Michael Bruch Interim Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Kenneth A. Pappa Vice President - Manufacturing and IT
Age: 54
Bio & Compensation  - Reuters
Mitchel Sivilotti Chief Biologist
Age: 36
Bio & Compensation  - Reuters
Mahendra S. Rao M.D., Ph.D. Director
Age: 54
Bio & Compensation  - Reuters
Denis Michael Rhein Director
Age: 54
Bio & Compensation  - Reuters